One medical provider of anti-radiation treatments has decided to boost its production and sales in Europe amid growing concerns regarding nuclear power and weapons.
Partner Therapeutics, the creator of the radiation sickness treatment drug Leukine, said it was increasing its drug production in Europe. The pharmaceutical company said it was reaching out to the World Health Organization and other entities to provide the necessary tools if nuclear war broke out.
<mediadc-video-embed data-state="{"cms.site.owner":{"_ref":"00000161-3486-d333-a9e9-76c6fbf30000","_type":"00000161-3461-dd66-ab67-fd6b93390000"},"cms.content.publishDate":1648556713341,"cms.content.publishUser":{"_ref":"0000017c-2d8e-d3f3-a7fc-7ffef6720000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"cms.content.updateDate":1648556713341,"cms.content.updateUser":{"_ref":"0000017c-2d8e-d3f3-a7fc-7ffef6720000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"rawHtml":"